Development of novel osteoarthritis therapy by targeting AMPK-β-catenin-Runx2 signaling
Daofu Zeng, Muhammad Ihtisham Umar, Zhenglin Zhu, Haobo Pan, William W. Lu, Guozhi Xiao, Yan Chen, Liping Tong, Di Chen
Abstract
Osteoarthritis (OA) is a debilitating chronic joint disease affecting large populations of patients, especially the elderly. The pathological mechanisms of OA are currently unknown. Multiple risk factors are involved in OA development. Among these risk factors, alterations of mechanical loading in the joint leading to changes in biological signaling pathways have been known as a key event in OA development. The importance of AMPK-β-catenin-Runx2 signaling in the initiation and progression of OA has been recognized in recent years. In this review, we discuss the recent progress in understanding the role of this signaling pathway and the underlying interaction mechanisms during OA development. We also discuss the drug development aiming to target this signaling pathway for OA treatment.